Special Report
Breast cancer remains one of the leading health concerns in Indonesia and ranks as the third deadliest cancer after lung and liver cancer. According to the...
May 02, 2025 | News
Genocury Biotech today revealed groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large ...
May 01, 2025 | News
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
April 28, 2025 | News
The global oligonucleotide market, once considered niche, has emerged as a pivotal segment in advanced therapeutics and innovative manufacturing strategies...
April 24, 2025 | Analysis
Asia Pacific bears nearly two-thirds of the global burden of moderate-to-severe vision impairment. Although 90 percent of vision impairment is preventable ...
April 24, 2025 | News
Cell therapy stands at the forefront of modern medicine, offering transformative potential for treating a wide spectrum of diseas...
April 22, 2025 | Report
In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...
April 16, 2025 | News
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...
April 16, 2025 | News
In a courtroom packed with legal heavyweights, global pharmaceutical giant F. Hoffmann-La Roche AG faced off against Indian generic manufac...
April 14, 2025 | Analysis
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study i...
April 10, 2025 | Report
On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept...
April 09, 2025 | News
Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...
April 03, 2025 | News
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...
April 01, 2025 | News
Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significan...
March 28, 2025 | News
Most Read
Bio Jobs
News
Editor Picks